Clinical Trial to Evaluate Safety and Efficacy of a Facial and Lip Moisturizer in Adult Subjects Undergoing a Facial Dermatologic Procedure With Fractional CO2 Laser

Exclusion Criteria

• •Has known allergies or adverse reactions to common topical skincare products including facial moisturizer, sunscreen and liquid soap.
• •Have known allergies or adverse reactions to the Pliaglis anesthetic cream that will be used for the dermatological facial procedure.
• •Presents with a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer).
• •Presents with primary/secondary lesions (scar - except from acne, ulcers, vesicles) or tattoos on test sites.
• •Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication.
• •Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
• •Immunosuppressive or steroidal drugs within 2 months before Visit 1\*
• •Non-steroidal anti-inflammatory drugs within 5 days before Visit 1\*
• •Antihistamines within 2 weeks before Visit 1\*
• •\* If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Study Physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "Concurrent/Concomitant Medication".
• •Is self-reported to be pregnant or planning to become pregnant during the study.
• •Subjects with a history of keloid formation.
• •Subject with a history of Herpes.
• •Has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.
• •Test positive for COVID-19 at visit 2 according to the rapid antigen test (COVID-19 Ag Immuno-Rapid Kit).
• •Is simultaneously participating in any other clinical study.
• •Is an employee/contractor or immediate family member of the PI, Study Site, or Sponsor.
• •History of a confirmed COVID-19 infection in the last 30 days.
• •Contact with COVID-19-infected person within 14 days prior to all on-site visits.
• •Any international travel within 14 days prior to all on-site visits including members in the same household.
• •Subjects with self-reported symptoms within the past 2 weeks:
• •Unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomach aches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, fever, or chest pain/tightness.
• •Temperature ≥ 38.0°C /100.4°F, measured.
• •Use of fever reducers within the past 2 days of each onsite visit.